
    
      Mytesi Â®(crofelemer) is an FDA-approved anti-diarrheal drug indicated for the symptomatic
      relief of non-infectious diarrhea in adult patients with HIV/AIDS on combination
      anti-retroviral therapy (CART). Crofelemer, a first-in-class intraluminally active,
      use-dependent chloride (Cl-) ion channel modulator that produces an antidiarrheal effect by
      reducing Cl- secretion and the accompanying high-volume fluid secretion into the GI lumen.

      This Phase 4 trial will explore the induced gut microbiome changes in comparison to a group
      of normal healthy volunteers also receiving crofelemer delayed release 125 mg tablets twice
      daily for 30 days.

      This is a non-randomized study. The study will enroll approximately 24 male or female
      subjects aged at least 18 years in three cohorts of approximately 8 subjects each.
    
  